PAHC PHIBRO ANIMAL HEALTH CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Global animal health and mineral nutrition solutions for livestock and companion animals, marketing ~800 product lines across 90 countries
• • New acquisition: Zoetis medicated feed additive portfolio acquired for $297.5M, adding $208.2M net sales in FY25 and 6 manufacturing sites in US, Italy, China
• • Strategic shift: Significant expansion in Animal Health segment driven by MFA product portfolio acquisition, Animal Health sales grow 36% to $963M
• • Notable metric: Total net sales up 27% YoY to $1.296B; Animal Health segment EBITDA up 53% to $222M; net assets increase 39% to $1.361B
• • Unusual fact: Inclusion of armed conflicts’ impact on results in MD&A due to ongoing geopolitical risks in Middle East and Eastern Europe

Risk Factors

• • Cybersecurity attacks increasing in sophistication, with potential for material business impact
• • AI technology adoption risks, including compliance with privacy regulations and ethical use across enterprise
• • Dependency on third-party suppliers with ongoing cybersecurity regulatory risk monitoring and standardized risk evaluations
• • Key-person risk: CIO with 45 years' experience critical to information security and risk management programs
• • Cyber insurance coverage regularly reviewed to support layered protection against cybersecurity incidents

Management Discussion & Analysis

• • Revenue $1.296B, up 27% YoY from $1.018B; Animal Health best segment $963M, up 36% YoY; Performance Products worst $80.2M, up 19%
• • Adjusted net income $84.9M, up 76% YoY from $48.4M; adjusted diluted EPS $2.09 vs $1.19 prior year
• • Operating margin ~8.5% ($110.5M operating income on $1,296M sales) up vs $53.3M on $1,018M (~5.2%) prior year calculated from given data
• • Operating cash flow $80.1M vs $87.6M prior year; Capital expenditures $38.3M vs $41.2M; Financing activities net cash inflow $207.1M (refinancing and acquisition financing); dividends paid $19.4M
• • Management expects adequate liquidity for next 12 months; risks include macroeconomic uncertainty, geopolitical conflicts (Israel-Hamas, Russia-Ukraine), and debt covenant restrictions on investments and dividends

What are the latest PAHC SEC filings in 2026?

PHIBRO ANIMAL HEALTH CORP (PAHC) has filed a 10-K annual report on August 27, 2025, a 10-Q quarterly report on May 6, 2026, an 8-K current report on July 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PAHC file its most recent 10-K annual report?

PHIBRO ANIMAL HEALTH CORP (PAHC) filed its most recent 10-K annual report on August 27, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PAHC 10-Q quarterly reports?

PHIBRO ANIMAL HEALTH CORP (PAHC)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every PAHC 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PAHC filed recently?

PHIBRO ANIMAL HEALTH CORP (PAHC)'s most recent 8-K was filed on July 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PAHC insider trading activity (Form 4)?

SignalX aggregates every PAHC Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PAHC file with the SEC?

PHIBRO ANIMAL HEALTH CORP (PAHC) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PAHC filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PHIBRO ANIMAL HEALTH CORP (PAHC).

What is PAHC's SEC CIK number?

PHIBRO ANIMAL HEALTH CORP (PAHC)'s SEC CIK (Central Index Key) number is 1069899. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1069899 to look up all PAHC filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PAHC return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from PHIBRO ANIMAL HEALTH CORP (PAHC) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.